Phenylpiracetam vs PT-141
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both Phenylpiracetam and PT-141 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Phenylpiracetam PT-141
Weight 218.25 Da —
Half-life ~3-5 hours ~2.7 hours
Type Racetam derivative (C12H14N2O2) Melanocortin receptor agonist
Key Benefits
Phenylpiracetam
01 Potent cognitive enhancement including improved memory, focus, and information processing speed
02 Psychostimulant properties that increase motivation, mental energy, and alertness without the jitteriness of classical stimulants
03 Physical performance enhancement through improved stamina, reduced perception of effort, and increased exercise tolerance
04 Enhanced cold tolerance -- a unique property among nootropics, originally developed for extreme-environment performance
05 Anxiolytic effects at standard doses, reducing stress reactivity without sedation
06 Anticonvulsant activity demonstrated in preclinical models
PT-141
01 FDA-approved pharmaceutical route
02 Predictable absorption profile
03 Effective for both male and female sexual dysfunction
04 Works within 45 minutes
05 Effective in PDE5 inhibitor-resistant cases
06 Central mechanism (not dependent on blood flow)
Dosing Protocols
Phenylpiracetam
100-200 mg, 1-2x/day / Once or twice daily (morning, or morning and early afternoon)
PT-141
Women: 1.75mg (FDA-approved); Men: 1-2mg; Start 0.5mg test dose for tolerance / As needed before sexual activity; max 1 dose per 24 hours
Female HSDD (FDA-approved) 1.75mg As needed, max 1 dose/24hr
Male Erectile Dysfunction 1-2mg As needed, 45-60min before activity
Female Arousal Disorder 0.75-1.25mg As needed, max 1 dose/24hr
Low Starting Dose 0.5mg Test dose for tolerance assessment
Side Effects
Phenylpiracetam
Insomnia, particularly if taken in the afternoon or evening -- the stimulant effects can persist for several hours after dosing
Irritability and overstimulation, especially at higher doses or when combined with other stimulants
Headache, most commonly caused by increased acetylcholine demand without adequate choline supplementation
Rapid tolerance development -- the most significant practical limitation, requiring intermittent dosing schedules to maintain efficacy
PT-141
Nausea (40%)
Flushing (20%)
Headache (11%)
Injection site reactions
Contraindications
Known hypersensitivity to phenylpiracetam or other racetams
Severe hypertension or cardiovascular disease (due to stimulant properties)
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic or renal impairment
Competitive athletes subject to WADA testing (phenylpiracetam is a prohibited substance under Section S6: Stimulants)
Uncontrolled hypertension
Cardiovascular disease
Use of nitrate medications
Pregnancy or breastfeeding
Research Evidence
Phenylpiracetam PT-141
Status Moderate Research FDA Approved
References 5 studies 4 studies
Latest — 2022
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.